Synthesis and preclinical evaluation of the 177Lu-DOTA-PSMA(inhibitor)-Lys3-bombesin heterodimer designed as a radiotheranostic probe for prostate cancer
Conclusion
The results warrant further preclinical studies to establish the 177Lu-radiotracer theranostic efficacy.
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: ORIGINAL ARTICLES Source Type: research
More News: Cancer | Cancer & Oncology | Gastroenterology | Nuclear Medicine | Prostate Cancer | SPECT | Study